Plus Therapeutics (PSTV) Competitors $1.64 +0.04 (+2.50%) (As of 09/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends PSTV vs. ECOR, POCI, OM, SURG, IRIX, ALUR, STIM, LFWD, DRIO, and MHUAShould you be buying Plus Therapeutics stock or one of its competitors? The main competitors of Plus Therapeutics include electroCore (ECOR), Precision Optics (POCI), Outset Medical (OM), SurgePays (SURG), IRIDEX (IRIX), Allurion Technologies (ALUR), Neuronetics (STIM), ReWalk Robotics (LFWD), DarioHealth (DRIO), and Meihua International Medical Technologies (MHUA). These companies are all part of the "medical equipment" industry. Plus Therapeutics vs. electroCore Precision Optics Outset Medical SurgePays IRIDEX Allurion Technologies Neuronetics ReWalk Robotics DarioHealth Meihua International Medical Technologies Plus Therapeutics (NASDAQ:PSTV) and electroCore (NASDAQ:ECOR) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their community ranking, dividends, earnings, media sentiment, analyst recommendations, institutional ownership, profitability, valuation and risk. Do institutionals and insiders hold more shares of PSTV or ECOR? 3.3% of Plus Therapeutics shares are held by institutional investors. Comparatively, 26.7% of electroCore shares are held by institutional investors. 2.3% of Plus Therapeutics shares are held by insiders. Comparatively, 13.1% of electroCore shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Is PSTV or ECOR more profitable? electroCore has a net margin of -66.84% compared to Plus Therapeutics' net margin of -240.15%. electroCore's return on equity of -165.17% beat Plus Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Plus Therapeutics-240.15% -805.57% -127.52% electroCore -66.84%-165.17%-78.53% Does the media refer more to PSTV or ECOR? In the previous week, Plus Therapeutics had 3 more articles in the media than electroCore. MarketBeat recorded 3 mentions for Plus Therapeutics and 0 mentions for electroCore. Plus Therapeutics' average media sentiment score of 0.32 beat electroCore's score of 0.00 indicating that Plus Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Plus Therapeutics Neutral electroCore Neutral Does the MarketBeat Community believe in PSTV or ECOR? electroCore received 99 more outperform votes than Plus Therapeutics when rated by MarketBeat users. Likewise, 62.12% of users gave electroCore an outperform vote while only 61.32% of users gave Plus Therapeutics an outperform vote. CompanyUnderperformOutperformPlus TherapeuticsOutperform Votes6561.32% Underperform Votes4138.68% electroCoreOutperform Votes16462.12% Underperform Votes10037.88% Which has more risk & volatility, PSTV or ECOR? Plus Therapeutics has a beta of 0.65, indicating that its stock price is 35% less volatile than the S&P 500. Comparatively, electroCore has a beta of 0.62, indicating that its stock price is 38% less volatile than the S&P 500. Do analysts recommend PSTV or ECOR? Plus Therapeutics currently has a consensus target price of $14.00, suggesting a potential upside of 753.66%. Given Plus Therapeutics' higher possible upside, equities research analysts plainly believe Plus Therapeutics is more favorable than electroCore.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Plus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00electroCore 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has stronger earnings and valuation, PSTV or ECOR? Plus Therapeutics has higher earnings, but lower revenue than electroCore. electroCore is trading at a lower price-to-earnings ratio than Plus Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPlus Therapeutics$4.91M1.91-$13.32M-$3.04-0.54electroCore$21.28M1.82-$18.83M-$2.85-2.27 SummaryelectroCore beats Plus Therapeutics on 9 of the 17 factors compared between the two stocks. Ad Brownstone ResearchAI expert reveals new Nvidia predictionEveryone’s talking about AI right now, but I’ve been talking about it for years. And now I’ve just released my latest prediction and believe it or not, I’m advising NOT pour all your money into Nvidia right nowClick here to see why Get Plus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PSTV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PSTV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat are MarkeBeat Followers?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PSTV vs. The Competition Export to ExcelMetricPlus TherapeuticsSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.36M$4.15B$5.51B$8.43BDividend YieldN/A46.03%4.98%4.06%P/E Ratio-0.5414.73143.0418.91Price / Sales1.9171.071,700.1786.54Price / CashN/A51.0137.4331.50Price / Book-5.474.354.944.55Net Income-$13.32M$3.15M$115.12M$225.08M7 Day Performance10.81%-1.54%9.01%3.29%1 Month Performance5.81%9.08%15.36%7.78%1 Year Performance30.16%35.27%33.07%14.53% Plus Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ECORelectroCore0.6882 of 5 stars0.69 / 5 stars$6.11+1.8%N/A+12.6%$36.70M$21.28M-2.1450Positive NewsPOCIPrecision Optics0.1942 of 5 stars0.19 / 5 stars$5.63+2.4%N/A-1.3%$34.17M$21.05M-20.1180Upcoming EarningsHigh Trading VolumeOMOutset Medical2.2196 of 5 stars2.22 / 5 stars$0.64+19.6%$4.64+630.7%-95.2%$33.10M$130.38M-0.19520SURGSurgePays4.0564 of 5 stars4.06 / 5 stars$1.66+2.2%$9.00+443.8%-63.1%$32.13M$112.99M1.4440Gap UpIRIXIRIDEX0.1804 of 5 stars0.18 / 5 stars$1.94+2.0%$2.00+3.2%-8.9%$31.50M$49.70M-2.89120ALURAllurion Technologies2.3934 of 5 stars2.39 / 5 stars$0.65+10.0%$3.17+387.9%-89.2%$31.12M$47.59M-0.17501Negative NewsSTIMNeuronetics3.8433 of 5 stars3.84 / 5 stars$0.96+0.9%$4.67+386.1%-29.8%$28.80M$72.07M-1.00180News CoverageLFWDReWalk Robotics2.5225 of 5 stars2.52 / 5 stars$3.22+2.2%$13.00+303.7%N/A$27.70M$23.28M-1.0460Gap DownDRIODarioHealth2.8745 of 5 stars2.87 / 5 stars$0.88+0.7%$4.00+354.5%-68.3%$26.33M$19.15M-0.52200News CoverageHigh Trading VolumeMHUAMeihua International Medical Technologies1.2147 of 5 stars1.21 / 5 stars$1.03-7.2%N/A-55.6%$25.83M$97.10M0.00620Gap UpHigh Trading Volume Related Companies and Tools Related Companies: electroCore Competitors Precision Optics Competitors Outset Medical Competitors SurgePays Competitors IRIDEX Competitors Allurion Technologies Competitors Neuronetics Competitors ReWalk Robotics Competitors DarioHealth Competitors Meihua International Medical Technologies Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PSTV) was last updated on 9/20/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump’s “Tax Free” Retirement StrategySince 1924 — over one hundred years — the US dollar has lost nearly 18x its value. If you're planning on re...Gold Safe Exchange | SponsoredThe election trade you can't losePolitics is an unpredictable game. But no matter what happens in the next few months... There's one thin...Investors Alley | SponsoredAre You Ready for a Small-Cap Rally?Jeff Bezos has just made a bold move into Quantum Computing as a Service (QaaS), a technology set to disrupt i...InvestorPlace | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredMust-Know for Trading OptionsOptions are becoming increasingly popular among investors – with demand hitting record highs for 3 years in a ...Unstoppable Prosperity | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredUnlock the Secret to Easy Wins with Iron CondorsDiscover the power of Iron Condor trades – a low-risk, high-reward strategy that allows you to profit consiste...Netpicks | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Plus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Plus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PSTV Stock Alerts